Jämför metoder
Granska de valda metoderna sida vid sida; rader som skiljer sig är markerade.
| Psoriasisartrit Livskvalitetsskala (PsAQoL)× | Systemisk lupus erythematosus sjukdomsaktivitetsindex 2000 (SLEDAI-2K)× | |
|---|---|---|
| Ämnesområde | Reumatologi | Reumatologi |
| Familj | Process / pipeline | Process / pipeline |
| Ursprungsår≠ | 1997 | 2002 |
| Upphovsperson≠ | McKenna & Doherty | Gladman et al. |
| Typ≠ | Patient-reported outcome (PRO) | Clinician-rated |
| Ursprungskälla≠ | Soderlin MK, Bergman S. Psychometric properties of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument: Rasch analysis. Arthritis Care Research. 2011;63(11):1589-1595. link ↗ | Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗ |
| Alias≠ | PsAQoL, PSAQoL | SLEDAI, SLEDAI-2K, SLE Disease Activity Index |
| Närliggande≠ | 4 | 3 |
| Sammanfattning≠ | The PsAQoL is a disease-specific patient-reported outcome measure of quality of life impact in psoriatic arthritis (PsA), a chronic inflammatory condition affecting joints and skin. Developed by McKenna and Doherty in 1997, PsAQoL comprises 20 items assessing the multidimensional impact of PsA on physical function, emotional well-being, work productivity, and social participation. PsAQoL captures the patient's lived experience of the disease, complementing clinical disease activity measures (CRP, joint counts) and providing a holistic view of treatment benefit in PsA research and practice. | The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease. |
| ScholarGateDatamängd ↗ |
|
|